XON - Intrexon Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.03
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.03
Open7.08
Bid7.00 x 900
Ask7.08 x 3000
Day's Range6.91 - 7.33
52 Week Range3.95 - 19.94
Volume2,609,447
Avg. Volume2,542,839
Market Cap1.134B
Beta (3Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-3.86
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference

    GERMANTOWN, Md. , June 13, 2019 /PRNewswire/ --  Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • GuruFocus.com6 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share.

  • GuruFocus.com6 days ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Capri Holdings, Odonate Therapeutics, Freeport-McMoRan, Intrexon and American Airlines

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Intrexon Corp.

    Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for XON with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold XON had net inflows of $571 million over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?
    Zacks8 days ago

    Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?

    Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com12 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $998,306 of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 203,321 shares of XON on 06/04/2019 at an average price of $4.91 a share.

  • Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology
    PR Newswire13 days ago

    Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly™ Aedes aegypti Technology

    CAMPINAS, Brazil, June 3, 2019 /PRNewswire/ -- Oxitec Ltd., a UK-based biotechnology company specializing in developing novel, environmentally-sustainable pest management solutions, today announced the successful completion of the first field trial in Brazil of its 2nd Generation Friendly™ Aedes aegypti technology. In partnership with the municipal vector control authorities in the city of Indaiatuba, the pilot project demonstrated the new strain's effectiveness in suppressing populations of the Aedes aegypti mosquito - the primary vector of dengue, Zika, chikungunya and yellow fever - in four densely populated urban communities across the city.

  • Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce
    PR Newswire13 days ago

    Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce

    DAVIS, Calif., June 3, 2019 /PRNewswire/ -- Intrexon Corporation (XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it is advancing GreenVenus™ Romaine lettuce to commercial trials.

  • Benzinga13 days ago

    Notable Insider Buys This Past Week: Coty, Zillow and More

    Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Zillow Group Inc (NASDAQ: Z) had a director return for more notable indirect share purchases this past week. Zillow's new business in buying and selling homes has helped boost its revenue.

  • Benzinga16 days ago

    Intrexon CEO Made Big Open-Market Bets In May

    Biotechnology company Intrexon Corp (NASDAQ: XON ) CEO Randal Kirk made five bundles of large purchases of the company's stock over the month of May. Recent trades listed below, courtesy of GuruFocus: ...

  • GuruFocus.com16 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $2.4 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 495,271 shares of XON on 05/30/2019 at an average price of $4.75 a share.

  • Fibrocell Up on FDA Designation for Gene Therapy Candidate
    Zacks17 days ago

    Fibrocell Up on FDA Designation for Gene Therapy Candidate

    Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

  • GlobeNewswire18 days ago

    Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB

    EXTON, Pa., May 29, 2019 -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective.

  • PR Newswire19 days ago

    Intrexon to Participate in 2019 BIO International Convention

    GERMANTOWN, Md. , May 28, 2019 /PRNewswire/ --   Intrexon Corporation  (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • GuruFocus.com22 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $1.9 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 410,050 shares of XON on 05/24/2019 at an average price of $4.69 a share.

  • GuruFocus.com25 days ago

    Intrexon Corp (XON) CEO Randal J Kirk Bought $2.9 million of Shares

    CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 633,631 shares of XON on 05/21/2019 at an average price of $4.65 a share.

  • CNBC27 days ago

    Cramer's lightning round: I feel bad if you own Intrexon — It's a loser

    It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.Intrexon XON : "This is a loser and I don't want to hear about it.

  • Intrexon CEO buys up more company shares
    American City Business Journals27 days ago

    Intrexon CEO buys up more company shares

    Intrexon Corp. (NASDAQ: XON) Chairman and CEO Randal Kirk has snapped up a bigger share of his public bioengineering company. Kirk controls Radford, Virginia-based venture capital firm Third Security LLC, which manages Third Security Capital Partners, Kapital Joe and NRM VI Holdings — all of which own Intrexon stock. In all, Kirk and his affiliates spent more than $9.2 million on the shares in mid-May, public filings show.